Literature DB >> 11948519

Fibrin as an alternative biopolymer to type-I collagen for the fabrication of a media equivalent.

E D Grassl1, T R Oegema, R T Tranquillo.   

Abstract

We report here on studies examining the use of fibrin as an alternative to collagen for the entrapment of neonatal aortic rat smooth muscle cells (SMCs) in the fabrication of media equivalents. The studies show increased collagen production by fibroblasts entrapped in fibrin, which suggests that fibrin may be used in the fabrication of tissue equivalents to promote increased protein synthesis and remodeling. However, one of the challenges of working with fibrin is the rapid degradation by SMCs. This degradation was effectively inhibited with the addition of epsilon-aminocaproic acid (EACA) to the culture medium in concentrations ranging from 0.25 to 1 mg/mL. We also present results showing that fibrin stimulates collagen production by SMCs. SMCs in fibrin produced 3.2 and 4.9 times the amount of collagen produced by SMCs in collagen when supplemented with 1 and 0.25 mg/mL EACA, respectively. More than half of the collagen produced appeared in the medium rather than the matrix. The collagen in the medium appeared to be processed beyond the proform and may be in an aggregate form. In addition, the presence of type-III collagen or a type-I trimer was indicated by the results of an analysis of the medium by autoradiography. Copyright 2002 Wiley Periodicals, Inc. J Biomed Mater Res 60: 607-612, 2002

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11948519     DOI: 10.1002/jbm.10107

Source DB:  PubMed          Journal:  J Biomed Mater Res        ISSN: 0021-9304


  66 in total

1.  Fibrin degradation enhances vascular smooth muscle cell proliferation and matrix deposition in fibrin-based tissue constructs fabricated in vitro.

Authors:  Katherine A Ahmann; Justin S Weinbaum; Sandra L Johnson; Robert T Tranquillo
Journal:  Tissue Eng Part A       Date:  2010-10       Impact factor: 3.845

2.  Hypoxic culture and insulin yield improvements to fibrin-based engineered tissue.

Authors:  Jason W Bjork; Lee A Meier; Sandra L Johnson; Zeeshan H Syedain; Robert T Tranquillo
Journal:  Tissue Eng Part A       Date:  2011-12-05       Impact factor: 3.845

Review 3.  Getting to the heart of tissue engineering.

Authors:  Luda Khait; Louise Hecker; Nicole R Blan; Garrett Coyan; Francesco Migneco; Yen-Chih Huang; Ravi K Birla
Journal:  J Cardiovasc Transl Res       Date:  2008-01-29       Impact factor: 4.132

4.  Tubular hydrogels of circumferentially aligned nanofibers to encapsulate and orient vascular cells.

Authors:  Mark T McClendon; Samuel I Stupp
Journal:  Biomaterials       Date:  2012-05-14       Impact factor: 12.479

5.  Influence of thrombin concentration on the mechanical and morphological properties of cell-seeded fibrin hydrogels.

Authors:  Shaneen L Rowe; Sungyun Lee; Jan P Stegemann
Journal:  Acta Biomater       Date:  2006-11-07       Impact factor: 8.947

Review 6.  Review: advances in vascular tissue engineering using protein-based biomaterials.

Authors:  Jan P Stegemann; Stephanie N Kaszuba; Shaneen L Rowe
Journal:  Tissue Eng       Date:  2007-11

7.  A fibrinogen-based precision microporous scaffold for tissue engineering.

Authors:  Michael P Linnes; Buddy D Ratner; Cecilia M Giachelli
Journal:  Biomaterials       Date:  2007-08-31       Impact factor: 12.479

8.  An ultrastructural analysis of collagen in tissue engineered arteries.

Authors:  Shannon L M Dahl; Megann E Vaughn; Laura E Niklason
Journal:  Ann Biomed Eng       Date:  2007-06-14       Impact factor: 3.934

9.  Cell-induced alignment augments twitch force in fibrin gel-based engineered myocardium via gap junction modification.

Authors:  Lauren D Black; Jason D Meyers; Justin S Weinbaum; Yevgeniya A Shvelidze; Robert T Tranquillo
Journal:  Tissue Eng Part A       Date:  2009-10       Impact factor: 3.845

10.  Transmural flow bioreactor for vascular tissue engineering.

Authors:  Jason W Bjork; Robert T Tranquillo
Journal:  Biotechnol Bioeng       Date:  2009-12-15       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.